Last $92.95 USD
Change Today -0.21 / -0.23%
Volume 486.9K
UTHR On Other Exchanges
As of 8:10 PM 07/10/14 All times are local (Market data is delayed by at least 15 minutes).

united therapeutics corp (UTHR) Snapshot

Previous Close
Day High
Day Low
52 Week High
12/24/13 - $116.65
52 Week Low
07/17/13 - $67.03
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

united therapeutics corp (UTHR) Related Businessweek News

View More BusinessWeek News

united therapeutics corp (UTHR) Details

United Therapeutics Corporation, a biotechnology company, develops and commercializes products to address the unmet medical needs of patients with chronic and life-threatening conditions worldwide. Its lead product comprises Remodulin, an injection used for the treatment of pulmonary arterial hypertension (PAH). The company also provides Tyvaso, an inhaled prostacyclin therapy; and Adcirca, a once-daily oral therapy for the treatment of PAH. In addition, it develops Orenitram, a prostacyclin analog for treatment of PAH; Ch14.18 MAb, an antibody for the treatment of neuroblastoma; Beraprost 314d, which is under Phase III clinical trials for the treatment of PAH; and PLacental eXpanded cells that are under Phase I trial for the treatment of PAH. Further, the company is involved in the pre-clinical stage development of TransCon Treprostinil and TransCon Beraprost for the treatment of PAH; glycobiology antiviral agents for the treatment of infectious diseases; UV-4B, an antiviral alpha-glucosidase inhibitor for the treatment of dengue; and engineered lungs and lung tissue that can be transplanted into patients suffering from PAH and other lung diseases. United Therapeutics Corporation was founded in 1996 and is headquartered in Silver Spring, Maryland.

706 Employees
Last Reported Date: 02/25/14
Founded in 1996

united therapeutics corp (UTHR) Top Compensated Officers

Founder, Chairman and Chief Executive Officer
Total Annual Compensation: $992.7K
President, Chief Operating Officer and Direct...
Total Annual Compensation: $808.1K
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $543.8K
Executive Vice President of Strategic Plannin...
Total Annual Compensation: $702.9K
Compensation as of Fiscal Year 2013.

united therapeutics corp (UTHR) Key Developments

United Therapeutics Corporation Approves Amendments to its Articles of Incorporation

United Therapeutics Corporation adopted the third amended and restated by-laws. The amended bylaws became effective immediately upon approval by the board, and contain new provisions, located at Article VIII, specifying Delaware state or federal courts as the exclusive forum for certain types of lawsuits, at the annual meeting of shareholders held on June 26, 2014.

United Therapeutics Corporation Presents at Jefferies 2014 Global Healthcare Conference, Jun-03-2014 02:30 PM

United Therapeutics Corporation Presents at Jefferies 2014 Global Healthcare Conference, Jun-03-2014 02:30 PM. Venue: Grand Hyatt, New York, New York, United States. Speakers: Andy Fisher, CSO.

United Therapeutics Corporation, Annual General Meeting, Jun 26, 2014

United Therapeutics Corporation, Annual General Meeting, Jun 26, 2014., at 09:00 US Eastern Standard Time. Location: 1110 Spring Street. Agenda: To elect the three Class III directors and nominated by Board of Directors to serve three-year terms until the 2016 annual meeting of shareholders and until their successors are duly elected and qualified or until their office is otherwise vacated; to vote on an advisory resolution to approve executive compensation; to ratify the appointment of Ernst & Young LLP as independent registered public accounting firm for 2014; and to consider and act upon such other business as may properly come before the annual meeting of shareholders and any adjournment or postponement thereof.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
UTHR:US $92.95 USD -0.21

UTHR Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Actelion Ltd SFr.109.80 CHF -1.90
Alexion Pharmaceuticals Inc $162.89 USD -1.63
Celanese Corp $64.12 USD -0.94
Nippon Shinyaku Co Ltd ¥2,942 JPY +15.00
Vertex Pharmaceuticals Inc $97.82 USD -0.28
View Industry Companies

Industry Analysis


Industry Average

Valuation UTHR Industry Range
Price/Earnings 20.3x
Price/Sales 4.0x
Price/Book 3.5x
Price/Cash Flow 17.9x
TEV/Sales 2.9x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact UNITED THERAPEUTICS CORP, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at